Wolfsperger Marcus, Greil Waldemar, Rössler Wulf, Grohmann Renate
Psychiatrische Privatklinik Sanatorium Kilchberg, Alte Landstrasse 70-84, 8802 Kilchberg, Switzerland.
J Affect Disord. 2007 Apr;99(1-3):9-17. doi: 10.1016/j.jad.2006.08.017. Epub 2006 Sep 20.
In a cross-section approach we investigated prescription practice in acute mania in 63 German, Swiss and Austrian hospitals between 1994 and 2004.
Our data were gathered from a large drug safety program (AMSP) within which on two reference days each year all administered drugs are recorded. For the present study, all cases with a primary diagnosis of acute euphoric mania (n=1291) or mixed-state mania (n=143) were identified. Prescription rates from two periods, 1994 to 1999 and 2000 to 2004, were compared.
In euphoric mania, prescription of lithium decreased by about one-fifth (43.3% to 34.5%, p<0.01), while prescription of anticonvulsants increased by one-half (from 40.0% to 60.7%, p<0.001). Administration of atypical antipsychotics more than doubled (18.5% to 43.9%, p<0.001), while use of typical antipsychotics decreased significantly (56.9% to 27.8%, p<0.001). Overall prescription rates of antipsychotics (79.6% vs. 81.6%) and antidepressants (14.0% vs. 15.5%) remained stable, while administration of tranquilizers increased significantly (26.3% to 34.3%, p<0.01). In mixed-state mania, similar trends over time to those seen in euphoric mania were observed for lithium (43.2% to 33.3%), anticonvulsants (50.0% to 69.7%, p<0.05) and tranquilizers (22.7% to 40.4%). Prescription rates of antipsychotics slightly increased (63.6% to 72.7%), while prescription of antidepressants slightly decreased (54.5% to 46.5%). Polypharmacy was a common phenomenon: patients with euphoric mania were treated with a mean number of 2.9+/-1.2 psychotropic agents, and patients with mixed-state mania with 3.3+/-1.5 psychotropic agents. Both groups showed a significant increase over time. Second-generation atypical antipsychotics were adopted quite rapidly for the treatment of acute mania considering the availability of the scientific evidence at that time. Off-label use was a common phenomenon. Deviations from recommended guidelines were found mainly in the use of antidepressant and antipsychotic drugs both in mixed-state and euphoric mania.
Naturalistic prescription studies like this may encourage a critical scrutiny of clinical treatment habits and may also drive further research thus moderating potential differences between evidence-based knowledge and everyday clinical practice.
我们采用横断面研究方法,调查了1994年至2004年间德国、瑞士和奥地利63家医院急性躁狂症的处方用药情况。
我们的数据来自一个大型药物安全项目(AMSP),该项目每年在两个参考日记录所有使用的药物。在本研究中,确定了所有原发性诊断为急性欣快性躁狂症(n = 1291)或混合状态躁狂症(n = 143)的病例。比较了1994年至1999年和2000年至2004年两个时期的处方率。
在欣快性躁狂症中,锂盐的处方率下降了约五分之一(从43.3%降至34.5%,p<0.01),而抗惊厥药物的处方率增加了一半(从40.0%增至60.7%,p<0.001)。非典型抗精神病药物的使用增加了一倍多(从18.5%增至43.9%,p<0.001),而典型抗精神病药物的使用显著减少(从56.9%降至27.8%,p<0.001)。抗精神病药物(79.6%对81.6%)和抗抑郁药物(14.0%对15.5%)的总体处方率保持稳定,而镇静剂的使用显著增加(从26.3%增至34.3%,p<0.01)。在混合状态躁狂症中,锂盐(从43.2%降至33.3%)、抗惊厥药物(从50.0%增至69.7%,p<0.05)和镇静剂(从22.7%增至40.4%)随时间呈现出与欣快性躁狂症相似的趋势。抗精神病药物的处方率略有增加(从63.6%增至72.7%),而抗抑郁药物的处方率略有下降(从54.5%降至46.5%)。联合用药是一种常见现象:欣快性躁狂症患者平均使用2.9±1.2种精神药物,混合状态躁狂症患者平均使用3.3±1.5种精神药物。两组随时间均显著增加。考虑到当时的科学证据,第二代非典型抗精神病药物在急性躁狂症治疗中被迅速采用。超说明书用药是一种常见现象。在混合状态和欣快性躁狂症中,主要在抗抑郁药和抗精神病药物的使用上发现了与推荐指南的偏差。
这样的自然主义处方研究可能会促使对临床治疗习惯进行批判性审视,也可能推动进一步的研究,从而缩小循证知识与日常临床实践之间的潜在差异。